Adlai Nortye to Showcase Novel Cancer Immunotherapy and RAS Inhibitor at AACR 2025
Adlai Nortye will present findings on two innovative cancer therapies at the AACR Annual Meeting in Chicago this April, highlighting their expanding oncology pipeline.
Adlai Nortye's AN2025 Shows Promise in Head and Neck Cancer Treatment
Adlai Nortye's short interest increased by 28.0% in December, reflecting market activity around the stock.
Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer
Adlai Nortye's Buparlisib, a pan-PI3K inhibitor, is in Phase III trials for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after anti-PD-(L)1 treatment.